Form 4 for XERS Xeris Biopharma Holdings, Inc.
Accepted 2024-08-02 00:00:00 ET · period of report 2024-08-01 · accession 0001867096-24-000144 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2024-08-02 | 2024-08-01 | XERS | McCulloch Kevin | See Remarks | A - Grant | $0.00 | +150.0K | 1.60M | +10% | $0 |
| D | 2024-08-02 | 2024-08-01 | XERS | McCulloch Kevin | See Remarks | A - Grant | $0.00 | +200.0K | 200.0K | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-08-01 | A | A | 150,000 | $0.00 | 1,601,953 | D | — | — | |
| 2 | Derivative | Stock Appreciation Right | 2024-08-01 | A | A | 200,000 | $0.00 | 200,000 | D | $2.43 · — to 2026-09-01 | 200,000 Common Stock | (F1) The award will vest in full on the two-year anniversary of the grant date. |